These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34343186)

  • 21. Invasive Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia: implications for India.
    Kolhapure S; Yewale V; Agrawal A; Krishnappa P; Soumahoro L
    J Infect Dev Ctries; 2021 Jun; 15(6):749-760. PubMed ID: 34242182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.
    Lucero MG; Dulalia VE; Parreno RN; Lim-Quianzon DM; Nohynek H; Makela H; Williams G
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004977. PubMed ID: 15495133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage.
    Kabir A; Newall AT; Randall D; Menzies R; Sheridan S; Jayasinghe S; Fathima P; Liu B; Moore H; McIntyre P; Gidding HF
    Vaccine; 2021 Mar; 39(12):1727-1735. PubMed ID: 33622589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
    Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
    Kabir A; Randall D; Newall AT; Moore HC; Jayasinghe S; Fathima P; Liu B; McIntyre P; Gidding HF
    Vaccine; 2023 Aug; 41(37):5454-5460. PubMed ID: 37507273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.
    Picazo J; Dueñas J; Ramirez A; Perez AR; Padilla E; Herrero S; Gallegos C; Culebras E; Balseiro C; Mendez C
    BMC Infect Dis; 2013 Oct; 13():503. PubMed ID: 24498901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland.
    Sigurdsson S; Eythorsson E; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á
    Vaccine; 2020 Mar; 38(12):2707-2714. PubMed ID: 32063434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
    Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature.
    Tsaban G; Ben-Shimol S
    Vaccine; 2017 May; 35(22):2882-2891. PubMed ID: 28449971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.
    Lucero MG; Dulalia VE; Nillos LT; Williams G; Parreño RA; Nohynek H; Riley ID; Makela H
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004977. PubMed ID: 19821336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
    Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
    Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
    [No Abstract]   [Full Text] [Related]  

  • 40. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy.
    Madhi SA; Cohen C; von Gottberg A
    Vaccine; 2012 Sep; 30 Suppl 3():C21-7. PubMed ID: 22939016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.